Cynata Therapeutics Ltd has released a press release.
September 2018 Quarterly Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- Engineered Cymerus™ MSCs Demonstrate Anti-Cancer Effects in Preclinical Studies
- MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical Studies
- Cynata MSCs Ameliorate CRS in Preclinical Study
- Cynata Advances to Official Meeting with Japanese PMDA
- Cynata GvHD Trial Meets all Safety & Efficacy Endpoints
Later from Cynata Therapeutics
- CYP Receives Notice of Allowance from European Patent Office
- Cynata Receives $1.3m R&D Tax Incentive Refund
- NHMRC Funding for Osteoarthritis Trial Using Cymerus MSCs
- NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus™ MSCs in Patients with Osteoarthritis
- Cynata Completes Clinical Study Report in GvHD
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics